

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/974,781
		Filing Date	10 October 2001
		First Named Inventor	Michael G. Kahn
		Group Art Unit	2166
		Examiner Name	Unknown
Sheet 1 of 2	Attorney Docket Number	FSTK 1004-1	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DBL	C1	DataEdge LLC. Indexes of Clinical Study Complexity, 1993-1999. In: Mathieu MP, editor. Parexel's Pharmaceutical R&D Statistical Sourcebook 2000. Waltham, MA: Parexel International Corp; 2000. p. 66.	
DBL	C2	DataEdge LLC. Indexes of Clinical Trial Costs Per Patient, 1993-1999. In: Mathieu MP, editor. Parexel's Pharmaceutical R&D Statistical Sourcebook 2000. Waltham, MA: Parexel International Corp; 2000. p. 67.	
DBL	C3	GROSSO W. E. et al.; "Knowledge Modeling at the Millennium (The Design and Evolution of Protégé-2000)," SMI Report Number: SMI-1999-0801 (1999), available at <a href="http://smi-web.stanford.edu/pubs/SMI_Abstracts/SMI-1999-0801.html">http://smi-web.stanford.edu/pubs/SMI_Abstracts/SMI-1999-0801.html</a> , visited 01/01/2000.	
DBL	C4	HOLFORD N. H. G.; KIMKO H. C.; MONTELEONE J. P. R., and PECK C. C.; "Simulation of Clinical Trials," Annu. Rev. Pharmacol. Toxicol. 2000, 40:209-34, 2000, Annual Reviews.	
DBL	C5	"ICH Harmonised Tripartite Guideline: General Considerations for Clinical Trials," International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use recommended for adoption on 17 July 1997, URL: <a href="http://www.ifpma.org/ich5e.html">www.ifpma.org/ich5e.html</a> , Accessed: 31 August 2001.	
DBL	C6	"ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice," International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use recommended for adoption on 1 May 1996, URL: <a href="http://www.ifpma.org/ich5e.html">www.ifpma.org/ich5e.html</a> , Accessed: 31 August 2001.	
DBL	C7	KROLL J. A.; DE BRUIN A.; GETZ K.; ESCHMANN K.; and ZISSON S.; "Study Conduct Delays are Getting Worse," In: Kroll JA, editor. An Industry In Evolution. Second ed. Boston, MA: CenterWatch; 1999. p. 99.	
DBL	C8	MUSEN M. A.; "Domain Ontologies in Software Engineering: Use of Protégé with the EON Architecture," Methods of Information in Medicine, F. K. Schattauer Verlagsgesellschaft mbH (1998); 37:540-50.	
DBL	C9	MUSEN M. A.; GENNARI J. H.; ERIKSSON H.; TU S. W.; and PUERTA A. R.; Protégé-II: Computer Support for Development of Intelligent Systems from Libraries of Components," MEDINFO 95 Proceedings. R. A. Greenes et al. (editors); 8(1):766-70.	
DBL	C10	MUSEN M. A.; ROHN J. A.; FAGAN L. M.; and SHORTLIFFE E. H.; "Knowledge Engineering for a Clinical Trial Advice System: Uncovering Errors in Protocol Specification," Report KSL-85-51, Proceedings AAMSI Congress 1986 (Levy, A.H. and Williams, B.T., eds.), pp. 24-27, Anaheim CA, May 1986.	
DBL	C11	SHEINER L. B. and STEIMER J. L.; "Pharmacokinetic/Pharmacodynamic Modeling in Drug Development," Annu. Rev. Pharmacol. Toxicol. 2000. 40:67-95, 2000, Annual Reviews.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

*(use as many sheets as necessary)*

Sheet	2	of	2
-------	---	----	---

Application Number	09/974,781
Filing Date	10 October 2001
First Named Inventor	Michael G. K...
Group Art Unit	2166
Examiner Name	Unknown
Attorney Docket Number	FSTK 1004-1

~~FEB 1 1 2007~~

TRADE MARK OFF

[illegible]

**Examiner  
Signature**

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**